Although the PD-1 pathway inhibitors tended to provide a stronger early survival benefit than anti-CTLA-4 in mice with single-hit candidiasis, improvement in 12-day mortality was comparable between the ICI treatments (32). Here, CTLA4 is linked to candidiasis.